The approach to evaluating the carcinogenic potential of pharmaceuticals is a matter of debate and has undergone important changes related to increasing knowledge of the mechanisms of carcinogenesis, accumulated data from carcinogenicity studies, and tech-nological progress. The discussions held during the International Conference of Harmoni-zation (ICH) led to the proposal of a basic principle for carcinogenicity testing: one rodent lifespan study plus an additional short-term study carrying mechanistic insight to the carcinogenicity endpoints. Alternatively, a second lifespan study is acceptable. This approach is in line with the development of alternative models, primarily genetically-modified mice that are conceived on the basis of known mechanisms of carcinogenesis. Such models have been evaluated through studies sponsored by the International Life Sciences Institute. These studies are in their final stage. Important data have already been presented.
This paper includes a critical analysis of the results available from the models and thinking in Europe about their contribution to risk assessment. It provides “a” European view, rather than “the” European view, of the problem, since the latter is dependent upon ongoing analysis of the available data being performed by the Committee for Proprietary Medicinal Products’ Safety Working Party.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Office of Science and Technology Policy. Chemical carcinogens: a review of the science and its associated principles. Federal Register. 1985;50:10372–10442.
Weisburger JH, Williams, GM. Carcinogen testing: current problems and new approaches. Science. 1981;214:401–407.
Commitee for Proprietary Medicinal Products/Safety Working Party (CPMP/SWP/1983). The Rules Governing Medicinal Products in European Union. Brussels, Belgium: Committee for Proprietary Medicinal Products; 1998;3B: 63.
Commitee for Proprietary Medicinal Products/International Conference on Harmonization. (CPMP/ICH/140/95). The Rules Governing Medicinal Products in European Union. Brussels, Belgium: Com-mitee for Proprietary Medicinal Products/International Conference on Harmonization; 1998;3B:73.
Purchase IFH. Current knowledge of mechanisms of carcinogenicity: genotoxins versus non-genotoxins. Human Experimental Toxicology. 1994;13:17.
Van Oosterhout JPJ, van der Laan JW, De Waal EJ, Olejniczak K, Hilgenfeld M, Schmidt V, Bass R. The utility of two rodent species in carcinogenicity risk assessment of pharmaceuticals in Europe. Reg Toxicol Pharmacol. 1997;25:6.
Bartsch H, Malaveille C. Prevalence of genotoxic chemicals among animal and human carcinogenic agents evaluated in the IARC monograph series. Cell Biol Toxicol. 1989;5:115.
Müller L, Kasper P. Human biological relevance and the use of threshold-arguments in regulatory genotoxicity assessment: experience with pharmaceuticals. Mutation Research. 2000;464:9.
Prives C, Hall PA. The p53 pathway. J Pathology. 1999;187:112.
Levine AJ. The tumour suppressor genes. Annu Rev Biochem. 1993;62:623.
French J, Haseman J. The p53-/- heterozygous knockout mouse model for short-term carcinogenicity testing. Presented at the Workshop on the Evaluation of Alternative Models for Carcinogenicity Testing, Washington, DC; November 2000.
Swift M, Chase C. Cancer in families with xeroderma pigmentosum. J Nat Can Inst. 1979;62:1415.
Setlow RB. Repair deficient human disorders and cancer. Nature. 1978:271:713.
Bootsma D, Hoeijmakers JHJ. Engagement with transcription. Nature. 1993;363:114.
Habraken Y, Sung P, Prakash L, Prakash S. Yeast Excision repair gene RAD2 encodes a single-stranded DNA endonuclease. Nature. 1993;366:365.
Steeg Hvan S, Beems RB, Benthem J van, van Kreijl C. The XPA-/- and the XPA-/-/p53-/- knockout mouse models for short-term carcinogenicity testing. Presented at the Workshop on the Evaluation of Alternative Models for Carcinogenicity Testing, Washing-ton, DC; November 2000.
Hoffmann JS, Fry M, Kandace, JJ, Williams J, Loeb LA. Codons 12 and 13 of H-ras protooncogene interrupt the progression of DNA synthesis catalysed by DNA polymerase α. Cancer Res. 1993;53:2895.
Krontiris TG, Devlin B, Karp DD, Robert NJ, Risch N. An association between the risk of cancer and mutations in the HRAS1 minisatellite locus. N Engl J Med. 1993;329:517.
Tong L, de Vos AM, Milbum MV, Jancarik J, Noguchi S, Nishimura S, Miura K, Ohtsuka E, Kim S-H. Structural differences between a ras oncogene protein and the normal protein. Nature. 1989:337:90.
Krengel U, Schlichting L, Scherer A, Schumann R, Frech M, John J, Sabsch W, Pai EF, Wittinghofer A. Three-dimensional structures of H-ras p21 mutants: Molecular basis for their inability to function as signal switch molecules. Cell. 1990;62:539.
Ando K, Saitoh A, Hino O, Takahashi R, Kimura M, Katsuki M. Chemically induced forestomach papillomas in transgenic mice carry mutant human c-Ha-ras transgenes. Cancer Res. 1992;52:978.
Saitoh A, Kimura M, Takahashi R, Yokoyama M, Nomura T, Izawa M, Sekiya T, Nishimura S, Katsuki M. Most turmors in transgenic mice with human c-Ha-ras gene contained somatically activated transgenes. Oncogene. 1990;Aug5(8):1195.
Brown K, Buchmann A, Balmain A. Carcinogen-induced mutations in the mouse c-Ha-ras gene provide evidence of multiple pathways for tumor progression. Proc Natl Acad Sci USA. 1990;87:538.
Leder A, Kuo A, Cardiff RD, Sinn E, Ledder P. v-Ha-ras transgene abrogates the initiation step in mouse skin tumorigenesis: effects of phorbol esters and retinoic acid. Proc Natl Acad Sci USA. 1990; 87:9178.
The Tg.AC Transgenic Model Assay Working Group. Characteristics of the Tg.AC Transgenic Mouse Model. Presented at the Workshop on the Evaluation of Alternative Models for Carcinogenicity Testing, Washington, DC; November 2000.
Tennant RW, French JE, Spalding JW. Identifying chemical carcinogens and assessing potential risk in short-term bioassays using transgenic mouse models. Environ Health Perspect. 1995;103:942.
The views presented in this paper are those of the authors and should not be understood or quoted as being made on behalf of the European Medicines Evaluation Agency or its scientific committees.
About this article
Cite this article
Silva-Lima, B., van der Laan, J.W. Current Status and Emerging Opportunities in Replacement of the Lifetime Mouse Cancer Bioassay. Ther Innov Regul Sci 36, 645–657 (2002). https://doi.org/10.1177/009286150203600319
- Carcinogenicity testing
- Transgenic mice
- Knockout mice